BAKER BROS. ADVISORS LP
Institutional investor · Portfolio as of Q2 2020
Top Holdings114 positions
| 47.3M | $8B | 35.4% | — | — | 6 qtrssince 2019-Q1 | Decreased 0 | |
Incyte Corp | 32M | $3.3B | 14.7% | $86.02 | +20.87% | 6 qtrssince 2019-Q1 | Increased 62 |
BEIGENE LTD | 11.8M | $2.2B | 9.8% | $132.00 | +42.73% | 6 qtrssince 2019-Q1 | Unchanged 0 |
ACADIA PHARMACEUTICALS INC | 41.9M | $2B | 9.0% | $27.58 | +75.76% | 6 qtrssince 2019-Q1 | Unchanged 0 |
Alexion Pharmaceuticals Inc | 8.8M | $983.3M | 4.3% | — | — | 6 qtrssince 2019-Q1 | Unchanged 0 |
BioMarin Pharmaceutical Inc | 7.6M | $936.1M | 4.1% | $88.83 | +37.54% | 6 qtrssince 2019-Q1 | Unchanged 0 |
KODIAK SCIENCES INC | 11.6M | $626.4M | 2.8% | $19.16 | +182.51% | 6 qtrssince 2019-Q1 | Unchanged 0 |
ASCENDIS PHARMA A/S | 3.4M | $501.4M | 2.2% | $117.70 | +23.37% | 6 qtrssince 2019-Q1 | Unchanged 0 |
INVITAE CORP | 11.9M | $359M | 1.6% | — | — | 6 qtrssince 2019-Q1 | Increased 62 |
MYOKARDIA INC | 3.2M | $305.7M | 1.3% | — | — | 6 qtrssince 2019-Q1 | Increased 74 |
AMARIN CORP PLC | 34.5M | $238.7M | 1.1% | — | — | — | Unchanged 0 |
ARGENX SE-ADR | 1M | $229.6M | 1.0% | $124.84 | +80.41% | 6 qtrssince 2019-Q1 | Unchanged 0 |
IGM Biosciences Inc | 3.1M | $229.5M | 1.0% | — | — | 4 qtrssince 2019-Q3 | Increased 48 |
Madrigal Pharmaceuticals Inc | 1.5M | $169.8M | 0.7% | $112.39 | +0.77% | 6 qtrssince 2019-Q1 | Unchanged 0 |
Mirati Therapeutics Inc | 1.4M | $161M | 0.7% | — | — | 6 qtrssince 2019-Q1 | Unchanged 0 |
Exact Sciences Corp | 1.8M | $160.5M | 0.7% | $91.87 | -6.37% | 3 qtrssince 2019-Q4 | Unchanged 0 |
Neurocrine Biosciences Inc | 906,986 | $110.7M | 0.5% | $87.28 | +43.79% | 6 qtrssince 2019-Q1 | Decreased 0 |
PRINCIPIA BIOPHARMA INC | 1.6M | $94.5M | 0.4% | — | — | 6 qtrssince 2019-Q1 | Decreased 0 |
FORMA THERAPEUTICS HLDGS INC | 2M | $93M | 0.4% | — | — | 1 qtr | New 49 |
CERUS CORP | 13.7M | $90.5M | 0.4% | $5.89 | +10.64% | 6 qtrssince 2019-Q1 | Unchanged 0 |
BAKER BROS. ADVISORS LP manages $22.7B across 114 positions as of Q2 2020. Top holdings: SGEN (35.4%), INCY (14.7%), ONC (9.8%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3/5.0.
Active quarter - 15 new positions, 11 exits, 20 increased. Top move: MYOK (INCREASED, conviction 74). Portfolio: $22.7B across 114 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR